---
title: "Anhui Wanbang Pharmaceutical Technology Co.,Ltd. (301520.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/301520.SZ.md"
symbol: "301520.SZ"
name: "Anhui Wanbang Pharmaceutical Technology Co.,Ltd."
industry: "Life Sciences Tools and Services"
datetime: "2026-05-21T18:01:10.843Z"
locales:
  - [en](https://longbridge.com/en/quote/301520.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/301520.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/301520.SZ.md)
---

# Anhui Wanbang Pharmaceutical Technology Co.,Ltd. (301520.SZ)

## Company Overview

Anhui Wanbang Pharmaceutical Technology Co.,Ltd. provides pharmaceutical research and clinical research services in China. The company offers service platform for pharmaceutical research, raw materials, clinical research, medical device services, biological sample analysis, SMO service, and statistical analysis. It also provides precision nutrition cooperation and ecosystem platform; and drug platform.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | CN Market |
| Website | [www.ahwbyy.cn](https://www.ahwbyy.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:14.000Z

**Overall: D (0.66)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 26 / 26 |
| Industry Median | B |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -35.09% |  |
| Net Profit YoY | -64.07% |  |
| P/B Ratio | 1.81 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2734732638.70 |  |
| Revenue | 233220192.04 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.00% | D |
| Profit Margin | 0.00% | D |
| Gross Margin | 15.25% | D |
| Revenue YoY | -35.09% | E |
| Net Profit YoY | -64.07% | E |
| Total Assets YoY | 1.57% | C |
| Net Assets YoY | 1.20% | C |
| Cash Flow Margin | 18.80% | D |
| OCF YoY | -35.09% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 5.33% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Anhui Wanbang Pharmaceutical Technology Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-35.09%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-64.07%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.81",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2734732638.70",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "233220192.04",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "15.25%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "-35.09%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-64.07%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "1.57%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.20%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "18.80%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-35.09%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "5.33%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 109.36 | 17/26 | 72.75 | 65.89 | 46.09 |
| PB | 1.76 | 3/26 | 1.98 | 1.90 | 1.82 |
| PS (TTM) | 11.38 | 22/26 | 10.07 | 9.13 | 8.32 |
| Dividend Yield | 0.00% | - | 0.87% | 0.82% | 0.77% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | WuXi AppTec (603259.SH) | A | A | C | A | B | B |
| 02 | Pharmaron (300759.SZ) | B | B | C | B | B | B |
| 03 | Chemexpress (688131.SH) | B | B | C | C | B | B |
| 04 | HitGen (688222.SH) | B | A | D | B | C | B |
| 05 | GEMPHARMATECH (688046.SH) | B | B | D | A | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/301520.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/301520.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/301520.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/301520.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**